Dr. Safieddin Safavi-Naeini Joins Biomark Scientific Advisory Team
(firmenpresse) -
Dr. SAFIEDDIN SAFAVI-NAEINI JOINS BIOMARK SCIENTIFIC ADVISORY TEAM
Vancouver, British Columbia - (December 2nd, 2014)-BioMark Diagnostics Inc. (BioMark) (CSE: BUX / FSE: 20B) is pleased to announce that it has appointed Dr. Safieddin Safavi-Naeini to its technical and scientific advisory team.
Dr. Safieddin Safavi-Naeini, Ph.D. is Professor in the Electrical and Computer Engineering Department and holds NSERC/Blackberry Industrial Research Chair in Intelligent Integrated Radio and Photonics at the University of Waterloo. Dr. Safavi-Naeimi is a leading hardware expert.
Rashid Ahmed, President and CEO, comments: Dr Safavi-Naeinis contribution to BioMarks technical and commercialization efforts would lever our technology platform to a different level. Dr. Safavi-Naeini brings world class expertise and we are honoured to have him join our team.
About BioMark Diagnostics Inc.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.
Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.
For further information on BioMark, please contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-282-6567
Email: info(at)biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Biomark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved or disapproved the content of this press release.
Leseranfragen:
" alt="Newnote Financial Announces Launch of Puretrade™ Crypto-Currency ExchangeDatum: 02.12.2014 - 15:16 Uhr
Sprache: Deutsch
News-ID 356658
Anzahl Zeichen: 2732
contact information:
Town:
Wien
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 120 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dr. Safieddin Safavi-Naeini Joins Biomark Scientific Advisory Team
"
steht unter der journalistisch-redaktionellen Verantwortung von
BioMark DIAGNOSTICS INC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
